#Urine Biochemical Detection Industry Growth | Explore Tumblr posts and blogs

mmarketdbmr · 12 days ago

Text

Inherited Metabolic Disorders Testing Market – Industry Trends and Forecast to 2030 Overview: Growth, Share, Value, Insights, and Trends

"Inherited Metabolic Disorders Testing Market Size And Forecast by 2030

According to Data Bridge Market Research Data Bridge Market Research analyses that the Global Inherited Metabolic Disorders Testing Market which was USD 603.4 Billion in 2022 is expected to reach USD 1125.15 Million by 2030 and is expected to undergo a CAGR of 8.10% during the forecast period of 2022 to 2030

Our comprehensive Inherited Metabolic Disorders Testing Market report is ready with the latest trends, growth opportunities, and strategic analysis. https://www.databridgemarketresearch.com/reports/global-inherited-metabolic-disorders-testing-market

**Segments**

- **By Disease Type**: The Inherited Metabolic Disorders Testing market can be segmented based on different types of inherited metabolic disorders such as phenylketonuria (PKU), maple syrup urine disease (MSUD), galactosemia, and others. Each of these diseases requires specific testing methods and technologies for accurate diagnosis and treatment.

- **By Test Type**: Tests for inherited metabolic disorders can be segmented into biochemical tests, genetic tests, enzyme activity tests, imaging tests, and others. Biochemical tests measure the levels of specific substances in the blood, urine, or tissue. Genetic tests identify changes in an individual's genes that may cause or contribute to an inherited disorder. Enzyme activity tests measure the activity of enzymes in the body to diagnose metabolic disorders accurately. Imaging tests like MRI and CT scans can also be used to detect abnormalities in certain metabolic disorders.

- **By End-User**: The market can be segmented based on end-users such as hospitals, diagnostic laboratories, research institutes, and others. Hospitals are the primary end-users for inherited metabolic disorders testing due to the availability of advanced diagnostic facilities and healthcare professionals. Diagnostic laboratories play a vital role in conducting various tests for accurate diagnosis. Research institutes are involved in developing new testing methods and technologies for inherited metabolic disorders.

- **By Region**: Geographically, the Inherited Metabolic Disorders Testing market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the market due to the high prevalence of metabolic disorders, increasing awareness, and the presence of major market players. Europe follows closely behind with advanced healthcare infrastructure and government initiatives to promote early diagnosis and treatment. The Asia Pacific region is expected to witness significant growth due to the rising cases of metabolic disorders and increasing healthcare expenditure.

**Market Players**

- **Thermo Fisher Scientific** - **PerkinElmer Inc.** - **Danaher** - **Merck KGaA** - **F. Hoffmann-La Roche Ltd** - **Agilent Technologies, Inc** - **Bio-Rad Laboratories, Inc** - **Abbott** - **Siemens Healthineers**

The Inherited Metabolic Disorders Testing market is highly competitive with the presence of several key players focusing on technological advancements, product launches, collaborations, and mergers & acquisitions to strengthen their market position. These companies invest heavily in research and development to introduce innovative testing solutions for a wide range of inherited metabolic disorders, driving market growth.

https://www.databridgemarketresearch.com/reports/global-inherited-metabolic-disorders-testing-market The global Inherited Metabolic Disorders Testing market is expected to witness significant growth in the coming years, driven by various factors such as the increasing prevalence of metabolic disorders, advancements in diagnostic technologies, and growing awareness among healthcare professionals and patients. The market segmentation based on disease type allows for targeted testing methods and treatments for specific inherited metabolic disorders like phenylketonuria (PKU) and galactosemia, enhancing the accuracy of diagnosis and personalized healthcare interventions. Similarly, segmenting by test type enables healthcare providers to choose the most appropriate testing method based on the patient's symptoms and medical history, leading to more precise and timely diagnosis of inherited metabolic disorders.

Furthermore, the segmentation by end-user highlights the essential role of hospitals, diagnostic laboratories, and research institutes in the Inherited Metabolic Disorders Testing market. Hospitals serve as key end-users due to their advanced diagnostic facilities and trained healthcare professionals, facilitating the diagnosis and treatment of patients with metabolic disorders. Diagnostic laboratories play a crucial role in conducting various tests, including biochemical, genetic, and enzyme activity tests, to provide accurate and reliable results for healthcare providers. Research institutes contribute to the market by developing innovative testing methods and technologies that can further improve the diagnosis and management of inherited metabolic disorders.

From a regional perspective, North America currently dominates the Inherited Metabolic Disorders Testing market, primarily due to the high prevalence of metabolic disorders, advanced healthcare infrastructure, and the presence of key market players. Europe follows closely, leveraging its robust healthcare system and government initiatives to promote early diagnosis and treatment of inherited metabolic disorders. The Asia Pacific region is poised for significant growth, driven by rising cases of metabolic disorders, increasing healthcare expenditure, and a growing focus on improving healthcare infrastructure and services.

In terms of market players, companies like Thermo Fisher Scientific, PerkinElmer Inc., Danaher, and Merck KGaA are among the key players driving innovation and advancements in the Inherited Metabolic Disorders Testing market. These companies emphasize research and development initiatives to introduce cutting-edge testing solutions and technologies that can improve the accuracy, efficiency, and accessibility of inherited metabolic disorders testing. Collaborations, product launches, and mergers & acquisitions are common strategies employed by market players to expand their market presence and gain a competitive edge in this rapidly evolving landscape.

Overall, the Inherited Metabolic Disorders Testing market presents significant opportunities for growth and innovation, driven by advancements in diagnostic technologies, increased awareness, and the strategic initiatives of key market players. As the demand for accurate and timely diagnosis of inherited metabolic disorders continues to rise, the market is expected to witness further expansion and diversification, benefiting both healthcare providers and patients in the quest for improved healthcare outcomes and quality of life.**Segments**

Global Inherited Metabolic Disorders Testing Market, By Disease Type: - Hurler Syndrome - Niemann-Pick Disease - Tay-Sachs Disease - Gaucher Disease - Fabry Disease - Krabbe Disease - Others

Therapy Type: - Enzyme Replacement Therapy - Cellular Transplantation - Small Molecule Based Therapy - Substrate Reduction Therapy - Gene Therapy - Drug Therapy

Route of Administration: - Oral - Parenteral - Others

End User: - Hospital and Clinics - Diagnostic Laboratories - Others

The global Inherited Metabolic Disorders Testing market offers a diverse range of segmentation opportunities based on disease type, therapy type, route of administration, and end users. Each segment provides a unique perspective on how the market caters to the needs of patients with inherited metabolic disorders. The disease type segment allows for targeted testing and treatment methods for specific disorders such as Hurler Syndrome, Tay-Sachs Disease, and Gaucher Disease, ensuring precise diagnosis and personalized healthcare interventions. The therapy type segment highlights the various treatment options available, including Enzyme Replacement Therapy, Gene Therapy, and Drug Therapy, offering healthcare providers multiple avenues to manage these complex disorders effectively. The route of administration segment emphasizes the importance of considering how therapies are delivered to patients, whether orally, parenterally, or through other means, to optimize treatment outcomes. Lastly, the end user segment underscores the crucial role of hospitals, diagnostic laboratories, and other healthcare facilities in providing comprehensive care for patients with inherited metabolic disorders.

**Market Players**

- Mayo Foundation for Medical Education and Research (MFMER) (U.S.) - MGC Diagnostics Corporation (U.S.) - Abbott (U.S.) - Admera Health - Promega Corporation (U.S.) - Alomone Labs (Israel) - Bio-Rad Laboratories, Inc. (U.S.) - Novartis AG (Switzerland) - AstaReal (Sweden) - Regeneron Pharmaceuticals Inc (U.S.) - Biophytis (U.K.) - AbbVie Inc. (U.S.) - Danone S.A. (France) - Pfizer Inc. (U.S.) - Abbvie Inc. (U.S.) - Bristol Myers Squibb Company (U.S.) - Biogen (U.S.) - GSK plc (U.K.) - F. Hoffmann-La Roche Ltd. (Switzerland)

The Inherited Metabolic Disorders Testing market is marked by the presence of key market players like Mayo Foundation for Medical Education and Research, Abbott, and Bio-Rad Laboratories, Inc., among others, that contribute significantly to advancements in diagnostics and treatments for inherited metabolic disorders. These industry leaders focus on research and development initiatives to introduce innovative testing solutions and therapies, thereby enhancing the accuracy and efficiency of diagnosis and management. Collaborations, partnerships, and mergers with other players in the healthcare industry are common strategies employed to expand market reach and offer comprehensive solutions to healthcare providers and patients. The involvement of such diverse market players underscores the collaborative efforts required to address the complex challenges posed by inherited metabolic disorders effectively.

In conclusion, the Inherited Metabolic Disorders Testing market offers a promising landscape for growth and innovation, driven by the collective efforts of market players, healthcare professionals, and researchers. By leveraging the segmentation insights across disease type, therapy type, route of administration, and end users, the market can tailor its offerings to meet the specific needs of patients with inherited metabolic disorders. With a diverse range of treatment options and advanced diagnostic technologies, the market is poised for substantial progress in improving healthcare outcomes and enhancing the quality of life for individuals affected by these challenging conditions.

The market is highly fragmented, with a mix of global and regional players competing for market share. To Learn More About the Global Trends Impacting the Future of Top 10 Companies in Inherited Metabolic Disorders Testing Market : https://www.databridgemarketresearch.com/reports/global-inherited-metabolic-disorders-testing-market/companies

Key Questions Answered by the Global Inherited Metabolic Disorders Testing Market Report:

What is the current state of the Inherited Metabolic Disorders Testing Market, and how has it evolved?

What are the key drivers behind the growth of the Inherited Metabolic Disorders Testing Market?

What challenges and barriers do businesses in the Inherited Metabolic Disorders Testing Market face?

How are technological innovations impacting the Inherited Metabolic Disorders Testing Market?

What emerging trends and opportunities should businesses be aware of in the Inherited Metabolic Disorders Testing Market?

Browse More Reports:

https://www.databridgemarketresearch.com/reports/global-liquid-chemical-sensors-markethttps://www.databridgemarketresearch.com/reports/global-paper-napkin-making-machine-markethttps://www.databridgemarketresearch.com/reports/global-neonatal-phototherapy-markethttps://www.databridgemarketresearch.com/reports/global-connected-health-personal-medical-devices-markethttps://www.databridgemarketresearch.com/reports/global-harvesting-equipment-market

Data Bridge Market Research:

☎ Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC: +653 1251 982

✉ Email: [email protected]"

#Inherited Metabolic Disorders Testing Market

0 notes

pranalip · 7 months ago

Text

Albumin & Creatinine Tests Market – Latest Trends Analysis And Forecast 2024-2033 | Global Insight Services

“Global Insight Services offers unparalleled market intelligence and strategic consulting services to businesses worldwide. Our expertise spans across various industries, including healthcare, technology, and consumer goods, providing comprehensive analysis and actionable insights. By leveraging advanced data analytics and in-depth market research, we empower our clients to make informed decisions, identify growth opportunities, and stay ahead of the competition”.

Global Albumin & Creatinine Tests Market is expected to reach $3.6 bn by 2031 growing at a CAGR of 14.7% between 2021 and 2031.

The urine albumin to creatinine ratio test is a common way to screen for high levels of albumin, which is known as albuminuria. This screening is most often done on people who have a greater risk of kidney disease comprising people with diabetes, high blood pressure, or a family history of kidney problems. Screening may also be recommended in older adults and people in some racial and ethnic groups. Screening for kidney disease may combine a urine albumin test with another kidney function test, known as an estimated glomerular filtration rate (eGFR) test, that assesses how well the kidneys are filtering the blood.

View The Full Report Here –https://www.globalinsightservices.com/reports/albumin-creatinine-tests-market

Market Drivers

Rising prevalence of kidney disorders

Kidney disease is one of the major causes of death worldwide. Such cases—comprising multiple kidney treatments—require the continuous monitoring of components such as creatinine and albumin and their ratios, for which multiple urine analysis products and techniques are utilized. Urine analysis has extensive applications in the diagnosis and management of kidney diseases. Biochemical urine analysis enables clinicians to assess the level of chemical compounds (such as creatinine, urobilinogen, bilirubin, ketones, and glucose) in the urine. Atypical levels of these compounds in the urine indicate chronic kidney diseases, acute kidney injuries, and acute renal failure. So, the growing incidence of kidney diseases will be the primary growth driver for this market, as it will ensure sustained demand for albumin and creatinine tests.

Market Opportunity

Integrated and automated systems for overall urine analysis

The combination of automated urine sediment and urine biochemical analysis in one system allows rapid and easy urine analysis. Currently, standalone automated urine sediment analyzers help standardize sediment & biochemical analysis with minimum operator interference and enable the fast analysis of urine samples. Such integrated systems have a high potential in the automated devices market and can help large hospitals and diagnostic labs to manage their workloads ecologically. Owing to that, this area has been identified as an opportunity in the market.

Market Restraints

High cost of automated analyzers

Most small hospitals and clinics with lower workloads still prefer semi-automated devices or manual analysis. Automated devices are primarily used by large hospitals with higher workloads; so, the revenue generation can justify the costs incurred in installing automated analyzers. This makes it difficult for automated analyzers to penetrate the market, specifically in developing economies, which is a major restraint factor to market growth.

Unlock Growth Potential in Your Industry – Get Your Sample Report Now-https://www.globalinsightservices.com/request-sample/GIS10235

Impact of COVID-19 on Albumin & Creatinine Tests Market

Acute Renal Failure (ARF) is generally detected and confirmed by increased creatinine levels in the urine, coupled with a sudden drop in the urine output. Adding to that, the rise in and high rate of hypoalbuminemia caused by COVID-19 (coupled with the rising geriatric population and other factors) is likely to increase the cases of AKI/ARF and thus support the market growth during the early half of the projection period.

Market Segments

By Product

Dipsticks & Kits

Analyzers

Cartridges

Cartridges for POC Analyzers

Cartridges for Table-Top Analyzer

Reagents & Other Consumables

By Type

Urine Tests

Urine Albumin Tests

Urine Creatinine Tests

Glycated Albumin

Blood & Serum Creatinine Tests

By End User

Hospitals & Clinics

Diagnostic Laboratories

Research Laboratories & Institutes

By Region

North America

Europe

Asia Pacific

Rest of the World

Market Players of Global Albumin & Creatinine Tests Market

The key players in the global albumin & creatinine tests market are Thermo Fisher Scientific, Inc., Roche Diagnostics, PromoCell GmbH, Abbott Laboratories, Siemens Healthineers, Danaher Corporation, Sysmex Corporation, Ortho Clinical Diagnostics, Randox Laboratories, FUJIFILM Wako Pure Chemical Corporation, Abbexa Ltd., ACON Laboratories, Inc., Arbor Assays Inc., ARKRAY Global Business Inc., Aviva Systems Biology, Axxora, LLC, BioAssay Systems, Nova Biomedical, Quantimetrix Corporation, RayBiotech Inc., Sekisui Diagnostics PEI Inc., Teco Diagnostics, Tulip Diagnostics, ulti med Products GmbH, and URIT Medical Electronic Co., Ltd. among others.

Buy Now@https://www.globalinsightservices.com/checkout/single_user/GIS10235

Research Scope

Scope – Highlights, Trends, Insights. Attractiveness, Forecast

Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others

Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain

Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments

Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis

Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis.

With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions

In-depth segmentation which can be customized as per your requirements

Free consultation with lead analyst of the report

Infographic excel data pack, easy to analyze big data

Robust and transparent research methodology

Unmatched data quality and after sales service

Global Insight Services LLC 16192, Coastal Highway, Lewes DE 19958 E-mail: [email protected] Phone: +1-833-761-1700 Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

0 notes

pranalipawarshinde · 8 months ago

Text

Albumin & Creatinine Tests Market – In Depth Insight Analysis to 2033

Global Albumin & Creatinine Tests Market is expected to reach $3.6 bn by 2031 growing at a CAGR of 14.7% between 2021 and 2031.

View The Full Report Here –https://www.globalinsightservices.com/reports/albumin-creatinine-tests-market

Market Drivers

Rising prevalence of kidney disorders

Market Opportunity

Integrated and automated systems for overall urine analysis

Market Restraints

High cost of automated analyzers

Unlock Growth Potential in Your Industry – Get Your Sample Report Now-https://www.globalinsightservices.com/request-sample/GIS10235

Impact of COVID-19 on Albumin & Creatinine Tests Market

Market Segments

By Product

Dipsticks & Kits

Analyzers

Cartridges

Cartridges for POC Analyzers

Cartridges for Table-Top Analyzer

Reagents & Other Consumables

By Type

Urine Tests

Urine Albumin Tests

Urine Creatinine Tests

Glycated Albumin

Blood & Serum Creatinine Tests

By End User

Hospitals & Clinics

Diagnostic Laboratories

Research Laboratories & Institutes

By Region

North America

Europe

Asia Pacific

Rest of the World

Market Players of Global Albumin & Creatinine Tests Market

Buy Now@https://www.globalinsightservices.com/checkout/single_user/GIS10235

Research Scope

Scope – Highlights, Trends, Insights. Attractiveness, Forecast

Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others

Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments

Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis

Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis.

With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions

In-depth segmentation which can be customized as per your requirements

Free consultation with lead analyst of the report

Infographic excel data pack, easy to analyze big data

Robust and transparent research methodology

Unmatched data quality and after sales service

Global Insight Services LLC 16192, Coastal Highway, Lewes DE 19958 E-mail: [email protected] Phone: +1-833-761-1700 Website: https://www.globalinsightservices.com/

About Global Insight Services:

#Albumin & Creatinine Tests Market #Albumin & Creatinine Tests Market Forecast #Albumin & Creatinine Tests Market Analysis #Albumin & Creatinine Tests Market Demand #Albumin & Creatinine Tests Market Growth

0 notes

kenresearchcompany · 2 years ago

Text

3 Key Insights on Competitive Landscape in the Global Immunoassays Market

Buy Now

Despite the Presence of about ~500 Competitors Comprising a Large Number of Country-Niche Players, Regional Players and, Global Players, finds a recent market study on Global Immunoassays Market by Ken Research

Immunoassays are bioanalytical techniques that detect and quantify analytes in biological samples, such as urine, blood, saliva, tissues, and cells by utilizing the precision of an antigen-antibody reaction. Clinical diagnostics, drug discovery, drug monitoring, and food testing are all common applications for such techniques - “Ken Research shares 3 key insights on the competitive landscape of this dynamic market from its latest research study”

Global Players that Constitute ~5% of Total Number of Competitors Hold Largest Revenue Share, While Regional Companies Hold ~20% Share in Terms of the Total Number of Players in the Market.

A comprehensive competitive analysis conducted during The Research Study found that the Global Immunoassay market is highly competitive with ~500 players, including globally diversified players, regional players, and a large number of country-niche players with their niche in advancement in medical technology for multiple end-user industries. The majority of the top global biopharmaceutical companies, including Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, and Danaher Corporation, maintained their leading positions in the forecasted period. The majority of players are actively focusing on advancements in immunoassays technology or methods, including:

The development of multiplexed immunoassays (MIAs) to perform various distinct assays in a single tube using the same sample during the same time.

Automation advancements for homogeneous systems/homogeneous enzyme immunoassays to high output and high-performance heterogeneous systems/heterogeneous enzyme immunoassays.

Some of these successfully morph to advance pharmaceutical analytical methods such as disease diagnosis, therapeutic drug monitoring, and bioanalytical/biochemical methods to identify the concentration of a particular chemical, enabling them to grow.

Leading Global Players’ Ongoing Efforts to Provide Pharmaceutical Analytical and Bioanalytical Solutions to End-User Industries, Particularly Following the Global Outbreak of the COVID-19 Pandemic, Are Driving Revenue Growth in This Market.

Detailed comparative analysis of key competitors available within The Research Study- shows that numerous biotechnology, and pharmaceuticals companies such as Radiometer, Diasorin, Bio-Rad laboratories, and more are highly focused on providing a significant number of healthcare solutions and advanced techniques that can be used across end-user industries to help better understand processes of viral, bacterial, or parasitic infection and how the immune system is sometimes interfered with. Furthermore, numerous companies and organizations are aggressively investing in advanced computation, data analytics, and increased R&D activities.

In May 2022, Radiometer, a Danish company that develops, manufactures, and markets solutions for blood sampling, blood gas analysis, endovascular monitoring, immunoassay testing, and related IT monitoring systems, announced that it will expand production and R&D capabilities at its current Turku facility, while also widening its global immunoassay business.

In April 2021, DiaSorin, an Italian biotechnology company, announced its partnership with Lumos Diagnostics, an Australian provider of rapid point-of-care diagnostics solutions, to launch the LIAISON IQ, a portable and cloud-connected immunoassay POC reader, along with a test to detect specific IgG antibodies against SARS-CoV-2 Spike human protein blood capillaries from a throat swab.

In September 2021, Bio-Rad Laboratories Inc., a U.S.-based research company devoted to biotechnology research, announced the introduction of the Bio-Plex Pro Human IgA and IgM SARS-CoV-2 immunoassay panels to identify IgA and IgM antibodies against four SARS-CoV-2 antigens.

The Ongoing COVID-19 has noticeably accelerated antibody testing worldwide, owing to the development and bioprocessing of COVID-19 vaccines and biotherapeutics.

The advent of the COVID-19 pandemic has accelerated the efforts to develop diagnostic tests to assess infectious diseases/viral infections and antibody responses, as well as vaccines and therapeutic applications. Consequently, the availability of laboratory assays that detect Covid-19 antibodies in human serum samples was essential for comprehending Covid-19 immune responses, assessing the virus's effect on an individual’s health, and assisting in the development of effective vaccines and therapeutics.

The global need for company and governmental sponsors to discover a suitable vaccine or therapeutic for Covid-19 has increased dramatically as the pandemic entered its extreme phase in 2020. Most international research authorities had also adopted an expedited operation or accelerated approval for COVID-19-related testing/antibody testing worldwide to ensure that they are treated as a priority. Furthermore, the ongoing COVID-19 pandemic has boosted the demand for infectious detection methods with low concentration levels and quick results. Despite significant advancements in methodologies and devices, immunochemical methods remain preferential for mass testing in the absence of specialized laboratories and highly qualified professionals. Microplate enzyme-linked immunosorbent assay (ELISA) with photometric detection and lateral flow immunoassay (LFIA) with visual results assessment are the two most commonly used immunoassays.

Increasing Government Initiatives, Strategies, and Investments in Pharmaceutical, and Biotech R&D, Notably Supporting Antibody Detection is Propelling the Immunoassays Market Growth.

Prior to the Covid-19 pandemic, government-led investment and involvement in life sciences were relatively limited worldwide, with the industry relying primarily on private funding. The pandemic led governments to concede that the structure needed to be changed. Since 2020, several governments across countries have raised funds for expensive premature vaccine development and production capacity expansion, as well as other critical pharmaceutical activities.

In September 2021, the U.S. Government (USG) empanelled a team of foremost virologists, immunologists, statisticians, and clinical trialists to identify the scientific and programmatic goals, and implement stringent testing, and sampling procedures.

In June 2021, Ubio Biotechnology Systems Pvt. Ltd., an Indian biotechnology company, developed the Industry Research Assistance Council (BIRAC) supported product 'SENSIT Rapid COVID-19 Ag kit' underneath the aegis of the COVID-19 Research Consortium for the rapid screening of SARS CoV-2 Nucleocapsid Protein with an assay time of 15 minutes.

In addition, nasopharyngeal swabs are used to collect samples from the suspected individual. This Indian Council of Medical Research (ICMR)-approved kit is a chromatographic immunoassay that allows healthcare personnel to read the test result optically.

For more information on the research report, refer to the below link:

Rapid Chromatographic Immunoassay Test Market: Ken Research

LinkedIn | Facebook | Twitter | YouTube

Ken Research

Ankur Gupta, Head Marketing & Communications

[email protected]

+91-9015378249

0 notes

broccolibushybrow-blog · 6 years ago

Text

Urimax 0.4 Mg Capsule - Uses, Dosage, Side Effects, Price, Composition

The Rhino products are one example of many sexual enhancement supplements containing unapproved, hidden ingredients that are the same as or chemically similar to the active ingredients in prescription medication. David R. McElwee suffered from a drop in blood pressure that led to a fatal heart attack two days after taking a male sexual enhancement product sold under the name Stiff Nights, according to the Star. Enter your name and email address to receive your free savings card. While legal prescription erectile dysfunction medication is popular all over the world and is readily available in South Africa, counterfeit production and consumption in the country is rampant. Its not always easy to let everyone know that you are using a medication for erectile dysfunction. Did you know that three-fourths of hunger pains are actually thirst pains? All drug companies have assistance programs to ensure that you get medications they are generating. In 2007, following the report of several case studies potentially linking PDE-5i use and sudden hearing loss, the Food and Drug Administration announced labeling changes for PDE-5i medications so that the risk of hearing problems was more prominently displayed. McGwin said one important consideration in evaluating the nature of the relationship between the drugs and hearing is the existence of a plausible biological mechanism of how these drugs might cause hearing loss. One should, however, bear in mind that the consult with a specialist before administering the drug is recommended if the best results are sought after. Nux vomica can cause dangerous drug interactions, especially with antipsychotics. This fast acting drug can show its effect within 24 to 36 hours. With early detection, doctors can suggest preventive measures like statins, blood pressure meds, revamping eating habits and getting more exercise. Due to growing age blood flow to reproductive parts of male slow down drastically and nerves and tissues get slow and lethargic in their responses to cause lack of stiffening of male reproductive organ to cause this problem. It actually works by inhibiting the actions of the PDE-5 proteins which are known to damage the muscles of the blood vessels and thus to cause them function improperly. After analyzing 28 previous studies on the link between ED and heart disease, the researchers found a connection between erectile dysfunction and poor endothelial function. Now that researchers have found this biochemical loop, new treatments targeting phosphorylation can help "intervene earlier in the arousal process than current medicines approved to treat erectile dysfunction," the release stated. If she is an older woman, this can also help to repair the fertility of a woman. No matter the cause of your erectile dysfunction, there is a strong probability that your doctor can deal with it, but you have to give him the opportunity. However, there are many good reasons why you should get a prescription to buy Viagra or Cialis. With the same ingredients in the same proportions, there is no difference in quality and a man will experience the same reaction with either choice. In fact this is certainly an important to get diabetic man or women. The fact that an herbal supplement is labeled "natural" does not mean it is safe or without any harmful effects. Take a look at 5 nutrition tips to begin your natural treatment for male impotence (erectile dysfunction). These words have allowed Joe Barton and Barton Publishing to help thousands of impotent men with an Erectile Impotence Remedy. Urimax 0.4 mg Capsule is an Alpha-adrenoreceptor antagonist which is used in men to decrease the urine outflow resistance due to an enlarged prostate gland. Most men test their masculinity when they spend time with their partner in bed. Erectile dysfunction (ED) is not a comfortable subject to discuss for most men. Chemicals Co. Ltd., Meda Pharmaceuticals, Inc., and Vivus, Inc. The industry for branded erectile dysfunction drugs is consolidated with key players involved in intense competition and rivalry. However, the industry is estimated to witness a decline in revenue over the forecast period owing to the patent expiration of key drugs in 2019. Moreover, reported side effects from the existing drugs are negatively affecting the industry growth. Brand loyalty and high acceptance levels of well-recognized brands, namely Viagra (sildenafil citrate), Cialis (tadalafil), and Levitra/Staxyn (vardenafil) are estimated to be the factors responsible for the wide establishment of erectile dysfunction drugs market in this region. PDE-5i drugs were originally designed to treat pulmonary hypertension and are now used extensively in the treatment of erectile dysfunction (ED). Viagra, the well-known erectile dysfunction drug, just got a huge price cut in the U.S. Reversing Diabetes Erectile Dysfunction 2 Sobenin IA et al. Eat foods like oysters, pumpkin seeds, watermelon seeds, wheat germ, veal liver, dark chocolate, sesame seeds and peanuts as these are good sources of zinc. A balanced diet plan tells you what foods you must eat, the time you must eat, the amount of food you must eat, online pharmacy and also consists of healthy snacks. Ideally you should check your sugar level every quantity of hours. Rising adoption of a sedentary lifestyle and increasing incidence of lifestyle diseases are further anticipated to fuel growth. In addition, medications like Viagra are also helpful. If you to be able to make tea in cold water you ought to choose the categories of tea leaves which containing low content of phosphorus like green tea and oolong tea benefits. It never seems like a big deal either way.

2 notes · View notes

mrfrblogresearch02 · 3 years ago

Text

Point of Care Diagnostics/Testing Market Demand, Cost Analysis And Latest Advancement in Medical Sector 2027

Market Highlights:

According to MRFR analysis, the global point of care diagnostics/testing Market Size is expected to register a CAGR of~11.6% from 2021 to 2027and hold a value of ~USD 36,740.3 million by 2027.

The global point of care diagnostics/testing market is driven by several factors, such as increasing demand for remote diagnosis, rising demand for early-stage diagnosis products, and growing demand for minimally or non-invasive diagnostic products. Other factors such as the introduction of mobile healthcare technologies and wearable diagnostic devices, the emergence of new technologies for monitoring and imaging are creating opportunities for the market players.

The market players are involved in various strategic collaborations, mergers & acquisitions, product launches, cooperative development of the product, and investing in stock to expand their worldwide presence. For instance, in July 2020, Becton, Dickinson and Company (US) launched a rapid POC antigen test to diagnose SARS-CoV-2 in 15 minutes. In June 2020, Celltrion Group (South Korea) announced to launch COVID-19 POC antigen testing kit. Furthermore, the prominent players focus on employee satisfaction, transforming their research utilities, and diversifying their distribution network. These factors will augment the market growth and will increase the market share during the forecast period. Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/10642 Regional Analysis: North America is estimated to dominate the point of care diagnostics/testing market, owing to the increasing demand for virtual and convenient diagnostic solutions, enhancement in healthcare regulations, and growing awareness about wellness and healthcare among the young population. Furthermore, the involvement/adoption of strategies like mergers & acquisitions by key players, government partnerships, and the development of new products are also propelling the market growth. Europe embraces the second-largest position in the point of care diagnostics/testing market due to the increasing number of IVD testing, molecular diagnostics, and the prevalence of respiratory diseases across the region. The industry players are involved in various business activities such as product launches, mergers and acquisitions, partnerships, and other commercial approaches. For instance, in May 2020, ProciseDx (US) launched 510k filing for CRP test in Europe for gastrointestinal disorders. The product launch aims to offer high lab-quality results to the patients. In addition, in July 2021, QuantuMDx (Singapore) launched Q-POC, a point-of-care diagnostics to detect SARS-CoV-2. The product is easy to use, affordable, and offers results in 30 minutes. Such business parameters are expected to propel the point of care diagnostic market in the forecast period.

Asia-Pacific is projected to be the fastest-growing regional market during the study period due to increasing demand for diagnostic tests such as blood gas tests, rapid blood coagulation tests, pregnancy tests, drug abuse screening, rapid diagnosis of cardiac markers, blood glucose testing, electrolyte analysis, urine analysis, and dry biochemical tests across the region. In addition, the increasing demand for multiple diagnostic devices coupled with the rising demand for accurate and efficient diagnostic and testing devices is driving the Asia-Pacific point of care diagnostics market.

The growth of the market in the Rest of the World is gaining importance over the last few years due to the increasing diagnosis of HbA1c and growing demand for glycated hemoglobin analysis. Moreover, the rising number of COVID-19 cases across the region is supporting the demand for POCs diagnosis. In addition, increasing investment in healthcare device manufacturing facilities is strengthening the product portfolio of the regional and global healthcare providers. The escalating demand for in-vitro diagnostics in South America is fueling the sales of POCs across the region. Such factors are expected to augment the market growth over the assessment period.

Segmentation:

The global point of care diagnostics/testing market is categorized into product, end user, mode of purchase, and platform. Based on the product category, the market has been segregated into glucose monitoring, pregnancy & fertility testing, infectious disease testing, drug abuse testing, coagulation monitoring, cardiometabolic monitoring, cancer/tumor marker testing, hematology testing, urinalysis testing, cholesterol, and others. The glucose monitoring segment is expected to hold a considerable share of the market in 2020. Increasing POC urine hCG (Human Chorionic Gonadotropin) tests to diagnose pregnancy is fueling the market growth. Companies such as Abbott (US) are offering total β-hCG for the early detection of pregnancy. In addition, rising POC testing for early tumor detection is strengthening the demand for POC diagnostic products.

Based on end user, the global point of care diagnostics/testing market has been classified as hospitals & clinics, diagnostics centers, homecare/self-testing, and others. Hospitals &clinics held the largest segment share in 2020, owing to easy maneuvering, sample processing, and quick delivery of results. A laboratory information system also manages and stores patient’s test data for further reference, which further drives the market growth. Additionally, the demand for homecare/self-testing is accelerating due to increasing health risks during the pandemic outbreak and rising connectivity between patients and health care providers.

Based on mode of purchase, the global point of care diagnostics/testing market has been classified as over-the-counter (OTC) testing products and prescription-based testing products. The OTC testing products aim to hold a larger market share in the mode of purchase category. OTC products are sold without the prescription for generic disease-diagnosed patients. Theycomply with certain parameters that include the highest standards for efficacy and safety, Good Manufacturing Practice (GMP) manufacturing, stability testing, and labeling under 21 CFR 201.66. According to the FDA, over 300,000 marketed OTC drug products are categorized into 80 therapeutic classes. The largevariety and availability of the products are driving the point of care diagnostics/testing market.

Based on the platform, the global point of care diagnostics/testing market has been classified as immunoassays, molecular diagnostics, dipstick, and others. Immunoassays is estimated to hold the largest segment share in 2020, owing to the increasing demand forthe products for testing particular antibodies or a specific antigen in blood or other body fluids. The immunoassays-based POC test is carried out in countries with low resources and facilities. Among the immunoassays, lateral flow immunoassays are highly used for quick diagnosis as they are sensitive to specific antigens and offer quick & accurate results.

Key Players:

Some of the key players in the global point of care diagnostics/testing market are Abbott Laboratories (US), Siemens Healthineers GmbH (Germany), Chembio Diagnostics, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (US), Becton, Dickinson and Company (US), Danaher Corporation (US), PTS Diagnostics (US), Nova Biomedical (US), Quidel Corporation (US), Sekisui Diagnostics (US), Trinity Biotech (Ireland), AccuBioTech Co., Ltd.(China), Instrumentation Laboratory Company (Werfen) (US), and EKF Diagnostics Holdings plc (UK) among others.

Browse Detailed TOC with COVID-19 Impact Analysis at:

https://www.marketresearchfuture.com/reports/point-of-care-diagnostics-testing-market-10642

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: [email protected]

#Point of Care Diagnostics/Testing Market #Point of Care Diagnostics/Testing Market trend #Point of Care Diagnostics/Testing Market analysis #Point of Care Diagnostics/Testing Market share

0 notes

latestanalysis · 3 years ago

Text

Global Albumin and Creatinine Tests Market By Component, By Type, By Enterprise Size , By Region, Industry Analysis Report to 2027

Global Albumin and Creatinine Tests Market

Albumin and Creatinine test is defined as type of urine test which is used to diagnose kidney diseases. Also, these tests are used to assess the risk of kidney diseases amongst patients diagnosed with diabetes or diabetic retinopathy. There are various types of tests used for detection of kidney diseases in hospitals and diagnostic centers such as urine albumin tests, urine creatinine test, glycated albumin test, and blood and serum creatinine tests.

The growing prevalence of kidney disorders is a one of the key driving factors which are expected to boost the global albumin and creatinine tests market growth. Kidney disease is a one of the major causes of death across the world. Such cases involve multiple kidney treatments, and also require the regular monitoring of components such as albumin & creatinine, and their ratios for which multiple urine analysis products & techniques are used. Urine analysis is a major application in the diagnosis & management of kidney diseases. Biochemical urine analysis provides clinicians to detect the level of chemical compounds including creatinine and albumin in the urine.

Request Sample Report @ https://qualiketresearch.com/request-sample/Albumin-and-Creatinine-Tests-Market/request-sample

Furthermore, the increase in incidences of type 2 diabetes or adult-onset diabetes, glomerulonephritis, high blood pressure is expected to drive the growth of global albumin and creatinine tests market growth over the forecast period. The integration of automated urine sediment & urine biochemical analysis is one system enables rapid & easy urine analysis. Also, standalone automated urine sediment analyzers helps standardize sediment and biochemical analysis with minimum operator interference & allow the rapid urine analysis. This is expected to accelerate the global albumin and creatinine tests market growth in near future.

High cost associated with automated analyzers may hamper the global albumin and creatinine tests market growth during this forecast timeline.

Market Segmentation

The Global Albumin and Creatinine Tests Market is segmented into product such as Dipsticks & Kits, Analyzers, Cartridges (Cartridges for POC Analyzers, and Cartridges for Table-Top Analyzers), and Reagents & Other Consumables, by type such as Urine Test (Urine Albumin Tests, Urine Creatinine Tests, Glycated Albumin), and Blood & Serum Creatinine Tests. Further, market is segmented into end user such as Hospitals & Clinics, Diagnostic Laboratories, and Research Laboratories & Institutes.

Also, the Global Albumin and Creatinine Tests Market is segmented into is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Regional Analysis

The North America is expected to hold the largest market share in the global albumin and creatinine tests market, due to the presence of local players in this region and easy availability of reagent kits in the region. APAC region will show the significant growth due to the expansion of pharma & diagnostic companies in this region. India and China will be the maximum revenue generating countries for global albumin and creatinine test market growth.

Top Key Players Analysis

Various key players are discussed in this report such as Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific, Inc., Roche Diagnostics, Siemens Healthineers AG, Sysmex Corporation, Randox Laboratories, Promocell Gmbh, Ortho Clinical Diagnostics, Fujifilm Wako Pure Chemical Corporation, etc.

Market Taxonomy

By Product

· Dipsticks & Kits

· Analyzers

· Cartridges

· Cartridges for POC Analyzers

· Cartridges for Table-Top Analyzers

· Reagents & Other Consumables

By Type

· Urine Test

· Urine Albumin Tests

· Urine Creatinine Tests

· Glycated Albumin

· Blood & Serum Creatinine Tests

By End User

· Hospitals & Clinics

· Diagnostic Laboratories

· Research Laboratories & Institutes

By Region

· North America

· Latin America

· Europe

· Asia Pacific

· Middle East & Africa

Browse full Report @ https://qualiketresearch.com/reports-details/Albumin-and-Creatinine-Tests-Market

Read Our more Report @

Global Dermatology Devices Market @ https://qualiketresearch.com/reports-details/Dermatology-Devices-Market

African Botanical Extract Market @ https://qualiketresearch.com/reports-details/African-Botanical-Extract-Market

Global Anti- CRISPR Protein Market @ https://qualiketresearch.com/reports-details/Anti-CRISPR-Protein-Market

Global Automotive Vision System Market @ https://qualiketresearch.com/reports-details/Automotive-Vision-System-Market

Global Dry Fruit Ingredient Market @ https://qualiketresearch.com/reports-details/Dry-Fruit-Ingredient-Market

#Albumin and Creatinine Tests Market size #Albumin and Creatinine Tests Market Share #Albumin and Creatinine Tests Market Trend #Albumin and Creatinine Tests Market Growth #Albumin and Creatinine Tests Market Application

0 notes

nickyshukla1 · 4 years ago

Text

Global Infectious Disease Diagnostics Market Overview, Size, Share and Trends 2017–2023

Summary - A new market study, titled “Global Infectious Disease Diagnostics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023” has been featured on WiseGuyReports

Infectious disease diagnostics are the procedures for identification and characterization of the causative agent of an infectious disease with the aid of diagnostic tools. These diagnostics provide crucial information for making right medical decisions. Infectious diseases caused by various micro-organisms such as viruses, bacteria, fungi, and parasites. Infectious diseases transmitted from person to person through either indirect or direct contact. Infectious diseases such as bacterial infections, fungal infections, and viral infections such as respiratory diseases, HPV, HIV, measles, malaria, dengue, cholera, and hepatitis B and C are gradually spreading worldwide. Infectious disease diagnostics can be based solely on clinical presentation or more rigorous diagnostic tests, such as microscopy, biochemical screens, culturing of an infectious agent, and molecular methods.

ALSO READ: https://www.marketwatch.com/story/infectious-disease-diagnostics-2020-global-market-outlookresearchtrends-and-forecast-to-2023-2020-11-06?siteid=bigcharts&dist=bigcharts

The key drivers for the growth of the infectious disease diagnostics market increase in the prevalence of dengue, malaria, and HIV, rise in the preference for rapid diagnosis, increase in government funding for the establishment of diagnostic centers, and technological advancements in diagnostic procedures expected to fuel the infectious disease diagnostics market. Furthermore, increase in the R&D activities for newer assays, changing demographics around the globe, and advances in healthcare infrastructure are expected to boost the infectious disease diagnostics market. However, high cost for the diagnostic procedures, lack of awareness about the novel diagnostic procedures, dearth of skilled professionals to perform diagnostic tests, and lack of reimbursement policies for several diagnostic test might hamper the infectious disease diagnostics market growth over the forecast period.

The infectious disease diagnostics market has been segmented on the basis of test type, technique type, product type, infection type, and the end-user

Based on the test type, infectious disease diagnostics market has been segmented into following:

Imaging test Magnetic Resonance Imaging (MRI) X-ray Computed tomography (C.T) Laboratory tests Blood test Urine test Stool test Spinal tap Throat swabs Biopsies Others

Based on the product type, infectious disease diagnostics market has been segmented into following:

Assay kits and consumables Instruments Services

Based on the infection type, infectious disease diagnostics market has been segmented into following:

Viral Bacterial CNS Fungal Cardiovascular Sexually transmitted infectious diseases Gastrointestinal Others

Based on the end-user, the infectious disease diagnostics market has been segmented into following:

Hospitals Diagnostic laboratories Home healthcare Ambulatory clinics Others

Geographically, the global infectious disease diagnostics market is in the flourishing stage, with the development of novel technologies by various players in the market. Increasing prevalence of the deadly infectious disease will drive the growth of the global infectious disease diagnostics market over the forecast period. For instance, according to World Health Organisation, global health observatory (GHO) data, in 2013, approximately 34-38 million people suffered from HIV infection worldwide. Innovation of technologically advanced devices with quick results, ease of usage, accuracy, and low-cost are expected to boost global infectious disease diagnostics market. For instance, in 2013, Abbott Molecular introduced a new range of real-time assays for hepatitis B virus, and hepatitis C virus infections on its m2000 platform. The majority of companies are making efforts to develop and commercialize cost-effective tools for the infectious disease diagnostics. Nowadays, the gold standard tests available for sexually transmitted disease and bacterial infection diagnosis, and these tests are expected to replace by molecular techniques in future.

Geographically, global infectious disease diagnostics market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the global infectious disease diagnostics market followed by Europe and Asia-Pacific. The largest share of North-America region is due to increase in the prevalence of infectious diseases especially in U.S. According to UNAIDS, in 2012, about 1.3 Mn patients were diagnosed with HIV in the U.S. These statistics are likely to increase over the coming years, if suitable treatment options are not provided in time. The European region is expected to emerge as significant market owing to improved healthcare infrastructure, and increase in prevalence of bacterial and viral diseases (according to WHO European Region, at the end of 2015, about 13.3 Mn people live with chronic hepatitis B, an estimated 15 Mn people with hepatitis C, and more than 2 Mn people with HIV), which are expected to fuel the growth of the infectious disease diagnostics market in European region. Moreover, Asia-Pacific is a key region for the growth of global infectious disease diagnostics during the forecast period, due to the high prevalence of infectious diseases, and increasing in healthcare expenditure. Moreover, due to increase in incidence and prevalence of infectious diseases such as bacterial infections and sexually transmitted diseases and rise in population expected to drive significant growth of the infectious disease diagnostics market in Asia-Pacific region.

Some of the players in global infectious disease diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Thermo Fischer Scientific (U.S.), Abbott Laboratories (U.S.), Bio-Rad Laboratories Inc. (U.S.), Becton, Dickinson & Company (U.S.), and DiaSorin S.p.A. (Italy) to name a few.

In 2016, Abbott unveiled Alinity, its unified family of innovative next-generation diagnostics system across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening, and molecular diagnostics

In 2015, Bio-Rad FDA has approved Bio-Rad’s BioPlex 2200 human immunodeficiency virus (HIV) Antigen-Antibody assay, used for detection of HIV antibodies and HIV antigens

In 2014, DiaSorin launched the new molecular diagnostic test for the detection of Toxoplasmosis

Report Outline:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023 The report covers in-detail insights about the competitor’s overview, key findings and their key strategies The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry The report tracks recent innovations, key developments and startup’s details that are working in the industry The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

FOR MORE DETAILS: https://www.wiseguyreports.com/reports/2753847-global-infectious-disease-diagnostics-market-market-estimation-dynamics-regional-share

About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

NORAH TRENT

[email protected]

Ph: +162-826-80070 (US)

Ph: +44 203 500 2763 (UK)

#Infectious Disease Diagnostics Market

0 notes

martynnx-blog · 6 years ago

Text

Biochemistry Analyzers Market Report: Global, Regional and Country Wise Data Break up and Analysis in a Latest Research

Instruments such as analyzers that are used in biochemistry are becoming technologically advanced in terms of precision and speed. The accuracy of biochemistry analyzers in analyzing urine and blood samples have benefited diagnostic centers and pathology labs in recent years. Moreover, modular design of these products are gaining significant attention. The varied demand of clinical laboratory business have generated the need for designing analyzers with wide range of capabilities and features. Fully automatic biochemistry analyzer analyzes many biochemical parameters of a blood sample such as protein, urea, and blood glucose, to detect various diseases associated with liver, kidney, and other metabolic disorders. Semi-automatic biochemistry analyzer is designed to measure various chemicals and other characteristics in a number of biological samples quickly. It measures the biochemical indexes of the sample and then, combines with other clinical information to help in identifying the disease and disease gene, evaluate organ functions, and determine the method of future therapy.

For In depth Information Get Sample Copy of this Report at: https://www.coherentmarketinsights.com/insight/request-sample/1873

Increasing R&D for low cost analyzers is expected to drive market growth

Increasing number of samples to be analyzed is increasing the demand for faster analytical methods that are capable of providing better information for decision making. The need for automated analyzers for environmental and industrial samples has increased the research for new and cost-effective strategies of automation and control of analytical systems. The widespread availability of open-source hardware along with novel analytical methods have opened the possibility of implementing standalone automated analytical systems at low cost. For instance, in 2011, Horiba Medical Ltd, Japan, received the Food and Drug Administration approval for Pentra C200, a fully automated bench-top analyzer that was designed as an economical option for smaller laboratories. However, new regulatory requirements such as RoHS have added complexity to instrument designing. High cost of tests and shortage of highly qualified and trained personnel are other factors restraining growth of the biochemistry analyzers market.

Some of the major players operating in the global biochemistry analyzers market are Abbott, Danaher Corporation, F.Hoffman-La Roche Ltd., Siemens AG, Thermo Fisher Scientific, Inc., Randox Laboratories Ltd., Meril, Hologic Inc., Beckman Coulter Inc., and Horiba Medical.

#Biochemistry Analyzers Market #Biochemistry Analyzers #Biochemistry Analyzers Market 2026

0 notes

mrfrblogresearch02 · 3 years ago

Text

Point of Care Diagnostics/Testing Market -Latest Trends, Demand, Growth, Opportunities and Outlook Till 2027

Market Highlights:

According to MRFR analysis, the global point of care diagnostics/testing Industry is expected to register a CAGR of~11.6% from 2021 to 2027and hold a value of ~USD 36,740.3 million by 2027.

Europe embraces the second-largest position in the point of care diagnostics/testing market due to the increasing number of IVD testing, molecular diagnostics, and the prevalence of respiratory diseases across the region. The industry players are involved in various business activities such as product launches, mergers and acquisitions, partnerships, and other commercial approaches. For instance, in May 2020, ProciseDx (US) launched 510k filing for CRP test in Europe for gastrointestinal disorders. The product launch aims to offer high lab-quality results to the patients. In addition, in July 2021, QuantuMDx (Singapore) launched Q-POC, a point-of-care diagnostics to detect SARS-CoV-2. The product is easy to use, affordable, and offers results in 30 minutes. Such business parameters are expected to propel the point of care diagnostic market in the forecast period.

Segmentation:

Key Players:

Browse Detailed TOC with COVID-19 Impact Analysis at:

https://www.marketresearchfuture.com/reports/point-of-care-diagnostics-testing-market-10642

About Market Research Future:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: [email protected]

#Point of Care Diagnostics/Testing Market

0 notes

market-insights-dbmr · 5 years ago

Text

Global Blood Screening Market Overview and Industry Trends 2026

Global blood screening market is expected to reach a healthy CAGR of 9.7% in the forecast period of 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

This blood screening market research report contains the most recent market information with which companies can get in depth analysis of healthcare industry and future trends. Wide-ranging evaluation of the market growth predictions and restrictions has also been studied in this report. This blood screening market research report offers wide-ranging analysis of the market structure for healthcare industry along with estimations of the various segments and sub-segments of the market. It offers key measurements, status of the manufacturers and proves to be a significant source of direction for the businesses and organizations.

Competitive Analysis: Global Blood Screening Market

Some of the prominent participants operating in this market are Enzo Biochem Inc., Meridian Bioscience, Inc. , BD , Bio-Rad Laboratories, Inc. , Thermo Fisher Scientific Inc., BioMérieux SA, Beckman Coulter, Inc., Abbott , F. Hoffmann-La Roche Ltd , Cepheid , GRIFOLS INTERNATIONAL, S.A. , Siemens AG , Ortho Clinical Diagnostics , Immucor, Inc., Hologic Inc., among others.

Get Sample Copy @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-blood-screening-market

Segmentation: Global Blood Screening Market

Global blood screening market is categorized based on basis of products & services, technology, disease type and end user.

On the basis of product & services the market is segmented into reagents and kits, instruments and software & services. Reagents and kits are further sub segmented into NAT reagents & kits, ELISA reagents & kits others as well. NAT reagents is further sub segmented into enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides and solutions alsolabeling and detection reagents. ELISA reagents & kits is further sub segmented into immunosorbents, controls, conjugates (antigen or antibody-conjugated enzyme), substrates (of enzymes) also sample diluents and wash solutions. Instruments segment is further segmented into instruments, product types and instruments, purchase type. In 2017, reagents & kits segment is expected to dominate the global blood screening market growing at the CAGR of 9.4% in the forecast period of 2018 to 2025.

In January 2017, F. Hoffmann-La Roche Ltd launched haematology testing solution. This solution is called the cobas m 511 integrated haematology analyser. This launch marked the entry for Roche Diagnostics in the haematology market.

On the basis of technology the market is segmented into nucleic acid test, enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assay, next-generation sequencing (NGS) and others. Nucleic acid test is further sub segmented into transcription-mediated amplification (TMA) and real-time polymerase chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) is further segmented into ELISA market, by platform, ELISA market, by generation. ELISA Market, By Platform is further sub segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA) and colorimetric immunoassay (CI). ELISA market, by generation is further segmented into first-generation ELISA, second-generation ELISA, third-generation ELISA and fourth-generation and above. In 2017, enzyme-linked immunosorbent assay (ELISA) segment is expected to dominate the global blood screening market growing at the CAGR of 9.8% in the forecast period of 2018 to 2025.

In September 2018, Thermo Fisher Scientific Inc. (U.S.), signed a definitive agreement with BD This business combines a strong technical service program with a variety of media and other products. This acquisition helped company to expand their business on global level with larger number of products.

On the basis of disease type, the market is segmented into respiratory diseases, diabetes mellitus, oncology, cholesterol, HIV/AIDS, cold & flu, infectious diseases and others. In 2017, oncology segment is expected to dominate the global blood screening marketgrowing at the highest CAGR of 10.3% in the forecast period of 2018 to 2025.

In June 2018, Thermo Fisher Scientific (U.S.) launched Oncomine TCR Beta-SR Assay. It is a new next-generation sequencing (NGS) solution in the field of immuno-oncology research. This helped company to expand their business by enhancing their product portfolio.

On the basis of end user the market is segmented into hospitals, clinics, diagnostic centers, blood bank and ambulatory surgical cenetrs. In 2017, diagnostic centers segment is expected to dominate the global blood screening market growing at the highest CAGR of 10.4%in the forecast period of 2018 to 2025.

In September 2016, Siemens Healthineers (Germany) acquired Conworx Technology GmbH (Germany) for point-of-care device interfaces and data management solutions. The company’s products and solutions designed helped in increasing efficiency and to reduce costs.

Product launch:

In March 2018, Bio-Rad Laboratories, Inc. launched IncRNA Workflow, a RT-qPCR workflow which is used to optimized for highly sensitive and specific quantification of long noncoding RNAs (lncRNAs) for gene expression analysis. The workflow provides a streamlined, cost-effective alternative to RNA-Seq for lncRNA discovery and validation.

In June 2018, Thermo Fisher Scientific launched Oncomine TCR Beta-SR Assay. It is a new next-generation sequencing (NGS) solution in the field of immuno-oncology research. This helped company to expand their business by enhancing their product portfolio.

In September 2018, Thermo Fisher Scientific Inc. , signed a definitive agreement with BD This business combines a strong technical services program with a variety of media and other products. This acquisition helped company to expand their business on global level with larger number of products.

Drivers: Global Blood Screening Market

RISE IN THE DEMAND OF BLOOD DONATIONS AND BLOOD DONORS:

Blood transfusion is an essential component of the health care field. It helps in saving millions of lives every year in both cases of routine and emergency conditions. Below mentioned are some of the statistics for blood donation and blood donors:

According to the World Health Organization (WHO), in 2017, it was reported that 112.5 million blood donations were collected from worldwide in which approximately half of the blood was collected from developed countries.

According to the World Health Organization (WHO), in 2017, it was reported that in 1000 people, the blood donation rate was 32.1 from high-income countries, 14.9 in upper-middle-income countries, 7.8 in lower-middle-income countries and 4.6 in low-income countries.

According to Australia Red cross blood service, 606,000 donors are there in Australia which are in 1,000 locations such as collection centres for blood donation available.

RISING PREVALENCE IN NUMBER OF DISEASES:

The prevalence of diseases and conditions such as Tuberculosis, HIV infection, Intestinal nematodes, diabetes mellitus, respiratory diseases, oncology, cholesterol, HIV/AIDS, cold & flu, infectious diseases and many others have increased considerably over a period of time. As numbers of diseases are increasing there is requirement for blood screening and diagnosis for further treatment of diseases.

According to WHO, alpha and beta thalassaemias are found to be the most common inherited single-gene disorders around the world. This disorder is with the highest prevalence with malaria at the places where it is endemic.As per the study conducted in Iran, it was estimated that approximately 8,000 pregnancies with risk takes place every year.

In 2016, according to Centers for Disease Control and Prevention (CDC), at the end of 2015, it was estimated 1.1 million persons with age 13 or older were suffering from HIV infection in the U.S. with an estimation of 162,500 (15.0%) persons whose infections had not been diagnosed.

In February 2018, according to verywell health, in South Africa 5,600,000 of people were estimated with HIV in 2009. In the total population of 53 million, the HIV prevalence for South Africa is found to be 10.6%.

Speak To Industry Experts, Request For Details Report At: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-blood-screening-market

Opportunity: Global Blood Screening Market

INCREASING MICROBIOLOGY SCREENING & MULTIPLEXING

The screening of blood involves the process that ensures whether the blood collected from people are safe or not. Based on the results of the screening, collected blood units are released for clinical research purpose or discarded if it has some contamination of bacteria or viruses or any other. For performing such screening there are different assays that help in determining the proper result.

Further with advancement, many of the other techniques are introduced with high benefits helping the market to grow in the upcoming days. The techniques are microbial screening and multiplexing technology.

Thermo Fisher Scientific (U.S.) provides microbial isolation and screening which include blood culture systems, clinical microbial identification, and microbiology specimen collection

In August 2015, Eurofins (France) launched accredited NGS tests useful for the identification of non-targeted microorganism. It helps in 16S rDNA screening for identifying the presence of microorganism communities in sample.

In July 2017, July 18, 2017–BD (Becton, Dickinson and Company) (U.S.) introduced new technologies which can automatically report and release negative urine cultures. This technology is transformed in the form of microbiology urine testing.

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email: [email protected]

0 notes

saojip13 · 5 years ago

Text

Infectious Disease Diagnostics Market Top Companies: BioMérieux SA, Thermo Fischer Scientific, Abbott Laboratories and Others

Global Infectious Disease Diagnostics Market Infectious disease diagnostics are the procedures for identification and characterization of the causative agent of an infectious disease with the aid of diagnostic tools. These diagnostics provide crucial information for making right medical decisions. Infectious diseases caused by various micro-organisms such as viruses, bacteria, fungi, and parasites. Infectious diseases transmitted from person to person through either indirect or direct contact. Infectious diseases such as bacterial infections, fungal infections, and viral infections such as respiratory diseases, HPV, HIV, measles, malaria, dengue, cholera, and hepatitis B and C are gradually spreading worldwide. Infectious disease diagnostics can be based solely on clinical presentation or more rigorous diagnostic tests, such as microscopy, biochemical screens, culturing of an infectious agent, and molecular methods.

Get a Sample Copy of this Report @ https://www.alexareports.com/report-sample/170633

The infectious disease diagnostics market has been segmented on the basis of test type, technique type, product type, infection type, and the end-user

Based on the test type, infectious disease diagnostics market has been segmented into following:

Imaging test Magnetic Resonance Imaging (MRI) X-ray Computed tomography (C.T) Laboratory tests Blood test Urine test Stool test Spinal tap Throat swabs Biopsies Others

Based on the product type, infectious disease diagnostics market has been segmented into following:

Assay kits and consumables Instruments Services

Based on the infection type, infectious disease diagnostics market has been segmented into following:

Viral Bacterial CNS Fungal Cardiovascular Sexually transmitted infectious diseases Gastrointestinal Others

Based on the end-user, the infectious disease diagnostics market has been segmented into following:

Hospitals Diagnostic laboratories Home healthcare Ambulatory clinics Others

Grab amazing discount here @ https://www.alexareports.com/check-discount/170633

In 2015, Bio-Rad FDA has approved Bio-Rad’s BioPlex 2200 human immunodeficiency virus (HIV) Antigen-Antibody assay, used for detection of HIV antibodies and HIV antigens

In 2014, DiaSorin launched the new molecular diagnostic test for the detection of Toxoplasmosis

Details of the market study:

Historical Data: 2014 & 2017

Base Year: 2018

Forecasts: 2019-2025

CAGR: 2019-2025

Market trend analysis in terms of drivers, restraints and opportunities

Industry analysis using Porter’s, PESTEL and SWOT

Market estimates and forecasts available for the following regions and countries:

Market players analysis in terms of company’s overview, financial performance, product/service benchmarking and strategic initiatives taken up by them

North America (U.S. & Canada)

Europe (UK & Germany)

Asia Pacific (Japan & China)

Latin America (Brazil, Mexico)

MEA (South Africa)

To Enquire About This Comprehensive Report@ https://www.alexareports.com/send-an-enquiry/170633

#infectious disease diagnostics market

0 notes

expertofmarketinsights-blog · 5 years ago

Text

Veterinary Chemistry Analyzers Market: Future and Technological Advancement 2026

A veterinary chemistry analyzer (VCA) is used for in-house veterinary use. These analyzers are used to determine the concentration of certain metabolites, proteins, electrolytes or drugs in samples of urine, plasma, serum, cerebrospinal fluid and/or other body fluids of animals. In other words, VCA is a blood and urine testing instrument that analyzes around 12 biochemical tests simultaneously, by using the samples of either urine, serum or plasma in around 6 minutes. The types of analyzers include, urine analyzers, blood gas & electrolyte analyzers, glucometers, and others, which are used by hospitals, medical labs, and for home use. There are several types of tests such as hematology test that includes the cell counter for blood counts, immunoassays for detecting antibodies, and tests for ions that measure voltage differences and others.

Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2677

Veterinary Chemistry Analyzers Market - Drivers

Increasing animal population, growing pet adoption, increasing demand for pet insurance, along with high animal health expenditure and increase in number of veterinary practitioners are the factors driving growth of the veterinary chemistry analyzers market. According to the data published by American Pet Product Association (APPA) in 2018, total pet healthcare expenditure in America in 2017 was US$ 69.51 billion, which reached to US$ 72.13 billion in 2018.

Increasing prevalence of zoonotic diseases is further contributing towards growth of the veterinary chemistry analyzers market. According to the Centers for Disease Control and Prevention (CDC) in 2017, 3 out of 4 emerging infectious diseases in people are transmitted through animals. E.coli infection, chickungunya, dengue, and malaria are some mild to severe zoonotic diseases. According to the World Health Organization, in 2015, around 212 million cases of malaria were recorded worldwide with 429,000 deaths. Therefore, increasing need for control measures for zoonotic diseases is expected to boost the market growth.

Key manufacturers in the market are focused on launching new veterinary chemistry analyzers, which is expected to boost the market growth. For instance, in November 2015, Diatron Group, global provider of hematology and clinical chemistry analyzers, launched a new 5-part differential veterinary hematology analyzer- the Abacus Vet5 in Dusseldorf at the Medica show.

Veterinary Chemistry Analyzers Market - Competitive Landscape

Some of the key players operating in the global veterinary chemistry analyzers market include, Abaxis Inc., IDEXX Laboratories Inc., Heska Corporation, DiaSys Diagnostics Systems, Derechos reservados Diconex, URIT Medical, Randox Laboratories Ltd., Eurolyser Diagnostica GmbH, ARKRAY Inc., and Alfa Wassermann Inc.

Purchase This Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/2677

Veterinary Chemistry Analyzers Market - Market Taxonomy

On the basis of modality, the global veterinary chemistry analyzers market is segmented into:

Benchtop

Portable

On the basis of product type, the global veterinary chemistry analyzers market is segmented into:

Instruments

Consumables

On the basis of animal type, the global veterinary chemistry analyzers market is segmented into:

Companion Animals

Livestock

On the basis of application, the global veterinary chemistry analyzers market is segmented into:

Blood Chemistry Analysis

Glucose Monitoring

Blood Gas & Electrolyte Analysis

Urinalysis

On the basis of end user, the global veterinary chemistry analyzers market is segmented into:

Hospitals

Clinical Laboratories

Veterinary Chemistry Analyzers Market - Regional Insights

On the basis of region, the global veterinary chemistry analyzers market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds dominant position in the global veterinary chemistry analyzers market. This is owing to increasing animal health expenditure and high demand for animal-derived food in the region. According to American Pet Products Association, the total pet industry expenditure which includes the food, supplies and over the counter medicine, in 2017 was US$ 69.4 billion.

Key market players in the region are focused on adopting acquisition strategies to expand their geographical presence. For instance, in May 2018, Zoetis Inc. and Abaxis Inc. announced the definite merger agreement in which Zoetis Inc. will acquire Abaxis Inc. This acquisition is expected to improve Zoetis Inc.’s presence in the veterinary diagnostics sector.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1–206–701–6702 Email: [email protected]

#Veterinary Chemistry Analyzers Market #Veterinary Chemistry Analyzers Market Size

0 notes

shubhambhosale1911-blog · 6 years ago

Text

Infectious Disease Testing Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2026

Since years, the human race has been prone to various contagious ailments. Although there has been a significant success in controlling epidemics at present day scenario testing and diagnostics of the virus, parasites, micro bacteria, fungi remain a priority especially in emerging economies around the globe. Government enforcement to control infectious diseases in general public, the rise in infectious diseases like HIV, hepatitis, tuberculosis, malaria, influenza, etc, rapid demand in the usage of molecular, biochemical techniques and diagnostic tests are factors promoting skyrocketing growth in global infectious disease testing market.

Other than the above factors increased health awareness about adverse effects of virus/foreign pathogen transmitted diseases coupled with the use of automation technology in healthcare domain is speculated to place global infectious disease testing market to achieve beyond $24 billion mark by 2026 end, registering a CAGR of 5.8% during the forecast period of 2019-2026.

Request a Sample Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=2278&page=requestsample

Below is the overview of global infectious disease testing market segmentation

Global Infectious Disease Testing Market, by Test Type

• Immunoassay Test • POCT Tests • Chromatography Tests • Others Immunoassay Test is high demand biochemical testing that can be used to detect antigens in various body fluids and blood at a molecular level. This vital information can reduce the patient’s hospital stay time by providing rapid test results. This segment remains most popular over other test types during the forecasted period.

Global Infectious Disease Testing Market, by Sample Type

• Urine • Blood • Others Blood sample tests will remain both inevitable and worthwhile as they will continue to provide valuable insights about infectious disease progression and measure effectiveness of treatments done. Thus taking a major chunk of global infectious disease testing market segment by sample type during the forecasted period.

Global Infectious Disease Testing Market, by Indication • Viral Infection • Bacterial Infection • Fungal Infection • Others

Global Infectious Disease Testing Market, by End-User • Pathology Laboratories • Hospitals • Maternity Centres • Clinics • Outpatient Centres • Academic Institutes Hospitals and pathology laboratories are estimated to register rewarding CAGR during the forecasted period. The rise in the number of patients needing diagnostic tests in hospitals is a major factor contributing to hospitals and path labs end-user segments rapid growth.

Global Infectious Disease Testing Market, by Region: • Europe • North America • APAC • Latin America • Rest of World While the emerging economies in APAC and Latin American region exhibit lucrative opportunities owing to the high prevalence of infectious diseases for forecasted period, North America and Europe continue to overpower the share of global infectious disease testing market. Owing to the stringent government policies and high penetration among end users.

Purchase a Copy & Ask For Discount: https://www.futurewiseresearch.com/request-sample.aspx?id=2278&page=askfordiscount

Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants

FutureWise Takeaways • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global infectious disease testing market on the basis of test type, sample type, indication, end-user and region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and an overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies

Inquire further details about this report at: [email protected]

About FutureWise Research:

We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future.

Company Name: FutureWise Research Contact Person: Vinay Thaploo Email: [email protected] Phone: +44 141 628 9353 / +1 970 279 4295 City: Leeds Country: United Kingdom Website: www.futurewiseresearch.com

#Infectious Disease Testing Market Share #Infectious Disease Testing Market Size #Infectious Disease Testing Market Trend #Infectious Disease Testing Market Forecast

0 notes

megasddw-blog · 6 years ago

Text

Urinalysis Test Market 2019 Covers Global Industry Share, Size, Gross Margin, Future Trends, Demand, Business Insight by Leading Key Players Forecast till 2023

MarketResearchFuture.com (MRFR) in it’s recently Announced study report asserts that the “Global Urinalysis Test Market”. Registering 6.3% CAGR Along with Top Companies, Mega Trends & market synopsis up to 2027.

Urinalysis Test Market Global Overview:

The Global Urinalysis Test Market is expected to grow at a CAGR of 6.3% during the forecast period. Urinalysis is a type of testing which is performed by evaluating the chemical, visual, and microscopic studies to detect cell fragments and substances such as crystals or casts in the urine. Urinalysis testing is a cost-effective, non-invasive test used as an indicator of health or disease.

The urinalysis testing ranges from manual reading of a visual urine test strip to the use of semi-automated analyzers to loading the sample on a fully automated urine chemistry analyzer. Rising demand for point-of-care testing and increasing prevalence of chronic diseases are the major drivers for the market growth.

According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the overall prevalence of Chronic Kidney Disease (CKD) in the general population is approximately 14%. Moreover, it was estimated that more than 70 % of medicare spending for CKD patients aged 65 and older was incurred by those who also had diabetes, congestive heart failure, or both.

Request Free Sample copy at https://www.marketresearchfuture.com/sample_request/839

Additionally, technological advancements boosts the market growth during the forecast period. Urinalysis is known to be the potential tool for physicians. Technological advancement is has found to improve the efficiency and reliability of results. Furthermore, most of the urine analyzers are now integrated with Electronic Health Records (EHR) to directly link the results into the patient’s database. For instance, Siemens AG is collaborated with Relaymed to bring labs cloud-based connectivity for the Siemens DCA Vantage analyzer and Clinitek Status point-of-care (POC) instruments. This will sent patient test results automatically from these POC instruments to physician-office EHR systems.

Segmentation Analysis:

The global urinalysis test market is segmented on the basis of product type, test type, application, and end user.

On the basis of product type, the market is segmented into instruments and consumables. The instruments type includes urine chemistry analyzer such as automatic urine analyzers and semi-automatic urine analyzers, automated urine sediment analyzers, point-of-care devices, and strip analyzer. The consumables are further segmented into plastic consumables, test strips, and chemical agents.

On the basis of test type, the market is segmented into macroscopic urinalysis, biochemical urinalysis, and sediments/microscopic urinalysis.

On the basis of application, the market is segmented into disease diagnosis including the diagnosis of diseases such as kidney disease, liver disease, diabetes, pregnancy tests, and others.

On the basis of end users, the market is segmented into hospitals, independent laboratories, and physician practices.

Key Players:

Dahaner, Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Siemens AG, ARKRAY, Sysmex Corporation and ACON Laboratories (U.S.).

Regional Analysis:

The Americas leads global urinalysis test market due to a well-developed healthcare sector and rising healthcare expenditures within the region. The Americas is followed by Europe. Countries like the U.K, France, Germany and Russia within the region are extensively grows the market in the presence of the developed healthcare sector. The Asia Pacific is the fastest growing region due to a huge patient population and rising healthcare expenditure. On the other hand, Middle East & Africa have the least share of the market.

Major TOC of Urinalysis Test Market Research Report - Global Forecast till 2023

1 Report Prologue

2 Market Introduction

3 Research Methodology

4 Market Dynamics

5 Market Factor Analysis

6 Global Urinalysis Test Market, By Product Type

7 Global Urinalysis Test Market, By Test Type

8 Global Urinalysis Test Market, By Application

9 Global Urinalysis Test Market, By End User

10 Global Urinalysis Test Market, By Region

11 Competitive Landscape

12 Company Profiles

13 MRFR Conclusion

14 Appendix

Browse Full Report at https://www.marketresearchfuture.com/reports/urinalysis-test-market-839

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: [email protected]

#Urinalysis Test Market

0 notes